Key Points
- Olema director Cyrus Harmon sold 3,489 shares on Jan. 14 at an average price of $29.12 for total proceeds of $101,599.68, trimming his stake to 737,770 shares (about $21.48M), a 0.47% decrease.
- Harmon also sold 2,881 shares on Dec. 22 at $28.53 for $82,194.93, marking multiple recent insider sales.
- Shares opened at $26.72 (down ~1.5%), Olema has a market cap of $1.83B with 50/200-day SMAs of $25.82/$13.71, and analysts’ consensus is a Moderate Buy with an average price target of $41.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 3,489 shares of the business's stock in a transaction dated Wednesday, January 14th. The shares were sold at an average price of $29.12, for a total transaction of $101,599.68. Following the transaction, the director directly owned 737,770 shares in the company, valued at approximately $21,483,862.40. The trade was a 0.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Cyrus Harmon also recently made the following trade(s):
- On Monday, December 22nd, Cyrus Harmon sold 2,881 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $28.53, for a total transaction of $82,194.93.
Olema Pharmaceuticals Stock Down 1.5%
Shares of NASDAQ OLMA opened at $26.72 on Wednesday. The company has a 50 day simple moving average of $25.82 and a 200-day simple moving average of $13.71. The company has a market capitalization of $1.83 billion, a P/E ratio of -14.29 and a beta of 1.92. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.03 and a quick ratio of 8.03. Olema Pharmaceuticals, Inc. has a 1 year low of $2.86 and a 1 year high of $36.26.
Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last posted its earnings results on Monday, November 10th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.05). On average, equities research analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.
Institutional Trading of Olema Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its position in Olema Pharmaceuticals by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company's stock worth $94,000 after acquiring an additional 477 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in Olema Pharmaceuticals by 55.4% during the second quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company's stock valued at $26,000 after purchasing an additional 2,168 shares during the last quarter. ProShare Advisors LLC boosted its holdings in Olema Pharmaceuticals by 21.1% during the second quarter. ProShare Advisors LLC now owns 14,766 shares of the company's stock worth $63,000 after buying an additional 2,569 shares in the last quarter. Bank of America Corp DE grew its position in Olema Pharmaceuticals by 0.4% in the third quarter. Bank of America Corp DE now owns 802,304 shares of the company's stock worth $7,855,000 after buying an additional 2,802 shares during the last quarter. Finally, FNY Investment Advisers LLC increased its holdings in shares of Olema Pharmaceuticals by 100.0% in the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company's stock valued at $42,000 after buying an additional 5,000 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.
Analyst Ratings Changes
OLMA has been the subject of several research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Olema Pharmaceuticals in a report on Wednesday, October 8th. JPMorgan Chase & Co. raised their target price on Olema Pharmaceuticals from $29.00 to $32.00 and gave the company an "overweight" rating in a report on Tuesday, November 18th. Guggenheim started coverage on shares of Olema Pharmaceuticals in a research note on Wednesday, October 8th. They set a "buy" rating and a $20.00 price target on the stock. The Goldman Sachs Group increased their price target on Olema Pharmaceuticals from $26.00 to $38.00 and gave the company a "buy" rating in a research report on Thursday, December 11th. Finally, Oppenheimer boosted their target price on shares of Olema Pharmaceuticals from $45.00 to $48.00 and gave the stock an "outperform" rating in a research note on Thursday, December 11th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $41.00.
Read Our Latest Stock Analysis on OLMA
Olema Pharmaceuticals Company Profile
(
Get Free Report)
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
